“Nobody is safe until everyone is safe” has become a mantra that reminds us of the importance of equitable access to vaccines. It is estimated that between 70% to 80% of the population.
A team of researchers from China and South Korea developed a machine-learning model that utilizes nodule characteristics on CT and pairs it with sociodemographic information to predict malignancy risk in patients with multiple pulmonary nodules. In testing, the algorithm called PKU-M yielded better results than previous models and also outperformed three thoracic surgeons and a radiologist in a prospective evaluation. Our prediction model, which was exclusively established for patients with multiple nodules, can help not only mitigate unnecessary surgery but also facilitate the diagnosis and treatment of lung cancer, said co-author Dr. Young Tae Kim, PhD, of Seoul National University Hospital in a statement from the American Association for Cancer Research (AACR).
Nektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
email article
In recognition of the 50th anniversary of the National Cancer Act, retiring chief medical officer Richard Schilsky, MD, of the American Society of Clinical Oncology (ASCO), reviews progress and major advances in cancer that have occurred since 1971.
A year after posting a negative trial in metastatic bladder cancer, AstraZeneca has voluntarily withdrawn the indication for durvalumab (Imfinzi) in the U.S. after consultation with the FDA. (
Endpoints News)
ASCO and Cancer Care Ontario published updated guidance for treating metastatic non-small cell lung cancer (NSCLC) associated with targetable mutations.
Sanofi and Regeneron announced FDA approval of cemiplimab (Libtayo) for first-line treatment of metastatic NSCLC with PD-L1 expression ≥50%.